September 9, 2022

Dear COVID-19 Therapeutics Providers,

Texas received a very small final distribution of bebtelovimab from the United States Government (USG) to be utilized exclusively for persons who are uninsured or underinsured.

- Providers are encouraged to waive or reduce the administration fee for uninsured and underinsured patients, but the administration fee must not exceed the CMS-established rates.
- Providers may not bill for the cost of the medication for USG-purchased supply.
- There is no date by which this bebtelovimab must be used for this patient population, but all USG bebtelovimab must be reported in HPOP.
- The administered count since last report and on-hand quantity of USG-purchased bebtelovimab must be reported in HPOP on Mondays and Thursdays, at a minimum. Be sure that all HPOP reporting is up to date for all products in your inventory prior to placing a request.
- USG-purchased and privately purchased bebtelovimab have different lot numbers and must be separated for reporting purposes.
- When you place this request in HPOP, you must agree to this attestation.

Bebtelovimab doses ordered through this final allocation are available for the under- and uninsured population within your area. Only those sites intending to use these doses to treat the under- and uninsured may continue to order bebtelovimab through HPOP. If you do not administer bebtelovimab to the under- and uninsured population, you should order bebtelovimab commercially through AmerisourceBergen. For any questions regarding access to commercial bebtelovimab please contact c19therapies@amerisourcebergen.com.
Thank you for your continued work to serve Texans with COVID-19.

**DSHS Information for COVID-19 Therapeutics Providers**